Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Phase 1:
Male or female, from 18 years to 49 years of age inclusive
Phase 2:
Male or female ≥50 years of age Phase 1 and Phase 2
Males: refrain from donating sperm, remain abstinent during study or agree to use condom
Females: Not pregnant. If a woman of childbearing potential, agree to use contraception or remain abstinent
You may not be if
History of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years of screening
Known hypersensitivity to any component of the pPCV, or any diphtheria toxoid-containing vaccine
Known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented human immunodeficiency virus (HIV) infection, functional or anatomic asplenia, or history of autoimmune disease
Coagulation disorder contraindicating IM vaccination
Recent febrile illness (defined as oral or tympanic temperature ≥100.4°F \[≥38.0°C\] or axillary or temporal temperature ≥99.4°F \[≥37.4°C\]) or received antibiotic therapy for any acute illness occurring within 72 hours of screening
Known malignancy that is progressing or has required active treatment within 3 years.(Note: participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ \[eg, breast carcinoma, cervical cancer in situ\] that have undergone potentially curative therapy are not excluded)
Pregnant
Received any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study, outside of the protocol.
Receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease
Received a blood transfusion or blood products, including immunoglobulin, 6 months before study vaccination or is scheduled to receive a blood transfusion or blood product
